World Journal of Gastroenterology - Baishideng Publishing Group

BPG is committed to discovery and dissemination of knowledge

Cited by in CrossRef

For:	Li J, Hou Y, Cai XB, Liu B. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. World J Gastroenterol 2016; 22(15): 4034-4040 [PMID: 27099447 DOI: 10.3748/wjg.v22.i15.4034]
URL:	https://www.wjgnet.com/1007-9327/full/v22/i15/4034.htm

(426) (435) (0) (0) (0) (8203) (42)

Number	Citing Articles
1	Yoh Asahi, Tatsuhiko Kakisaka, Toshiya Kamiyama, Tatsuya Orimo, Shingo Shimada, Akihisa Nagatsu, Takeshi Aiyama, Yuzuru Sakamoto, Kazuki Wakizaka, Shunsuke Shichi, Hirofumi Kamachi, Akinobu Taketomi. Improved survival outcome of curative liver resection for Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma in the era of tyrosine kinase inhibitors. Hepatology Research 2025; 55(1) doi: 10.1111/hepr.14098
2	Jia-jia Du, Fan Yang, Wei Dong, Zun-yi Zhang, Qi Cheng, Er-lei Zhang. Revisiting the role of local treatments in the era of targeted therapy and immunotherapy for hepatocellular carcinoma. World Journal of Surgical Oncology 2025; 23(1) doi: 10.1186/s12957-025-03963-3
3	Ao Huang, Xin-Rong Yang, Wen-Yuan Chung, Ashley R. Dennison, Jian Zhou. Targeted therapy for hepatocellular carcinoma. Signal Transduction and Targeted Therapy 2020; 5(1) doi: 10.1038/s41392-020-00264-x
4	Lucia Cerrito, Brigida Eleonora Annicchiarico, Roberto Iezzi, Antonio Gasbarrini, Maurizio Pompili, Francesca Romana Ponziani. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. World Journal of Gastroenterology 2019; 25(31): 4360-4382 doi: 10.3748/wjg.v25.i31.4360 Abstract(1600) \| Core Tip(1604) \| Full Article(HTML)(12990) \| Full Article (PDF)-2811K(1656) \| Full Article (Word)-516K(370) \| Audio-554K(43) \| Peer-Review Report-173K(383) \| Answering Reviewers-150K(373) \| Times Cited (102) \| Total Visits (16230) \| Open
5	Jian-Hong Zhong, Xue-Ke Du, Bang-De Xiang, Le-Qun Li. Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial. World Journal of Hepatology 2016; 8(23): 957-960 doi: 10.4254/wjh.v8.i23.957 Abstract(1582) \| Core Tip(1514) \| Full Article(HTML)(4999) \| Full Article (PDF)-641K(644) \| Full Article (Word)-157K(340) \| Audio-450K(28) \| Peer-Review Report-100K(322) \| Answering Reviewers-93K(336) \| Times Cited (9) \| Total Visits (6868) \| Open
6	Han Ah Lee, Chai Hong Rim. Efficacy of Local Treatments for Hepatocellular Carcinoma Involving the Inferior Vena Cava and/or Right Atrium. Journal of Hepatocellular Carcinoma 2020; doi: 10.2147/JHC.S285357
7	Jian Li, Wen-qiang Wang, Rong-hua Zhu, Xing Lv, Jin-lin Wang, Bin-yong Liang, Er-lei Zhang, Zhi-yong Huang. Postoperative adjuvant tyrosine kinase inhibitors combined with anti-PD-1 antibodies improves surgical outcomes for hepatocellular carcinoma with high-risk recurrent factors. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1202039
8	Xu Feng, Guo-Ying Feng, Jie Tao, Yu-Pei Ao, Xin-Hua Wu, Shi-Guai Qi, Zheng-Rong Shi. Comparison of different adjuvant therapy regimen efficacies in patients with high risk of recurrence after radical resection of hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology 2023; 149(12) doi: 10.1007/s00432-023-04874-0
9	Kuan-Chun Hsueh, Cheng-Chun Lee, Pi-Teh Huang, Chih-Yu Liang, Shun-Fa Yang. Survival Benefit of Experience of Liver Resection for Advanced Recurrent Hepatocellular Carcinoma Treated with Sorafenib: A Propensity Score Matching Analysis. Current Oncology 2023; 30(3) doi: 10.3390/curroncol30030243
10	Feng Che, Yi Wei, Qing Xu, Qian Li, Tong Zhang, Li-Ye Wang, Man Li, Fang Yuan, Bin Song. Noninvasive identification of SOX9 status using radiomics signatures may help construct personalized treatment strategy in hepatocellular carcinoma. Abdominal Radiology 2024; 49(9) doi: 10.1007/s00261-024-04190-2
11	Kazuhiko Sakamoto, Hiroaki Nagano. Surgical treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus. Hepatology Research 2017; 47(10) doi: 10.1111/hepr.12923
12	Riccardo Nevola, Augusto Delle Femine, Valerio Rosato, Loreta Anesti Kondili, Maria Alfano, Davide Mastrocinque, Simona Imbriani, Pasquale Perillo, Domenico Beccia, Angela Villani, Rachele Ruocco, Livio Criscuolo, Marco La Montagna, Antonio Russo, Aldo Marrone, Ferdinando Carlo Sasso, Raffaele Marfella, Luca Rinaldi, Nicolino Esposito, Giuseppe Barberis, Ernesto Claar. Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era?. Cancers 2023; 15(11) doi: 10.3390/cancers15112950
13	Wang Gu, Zhong Tong. Sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) and microvascular infiltration: a systematic review and meta-analysis. Journal of International Medical Research 2020; 48(8) doi: 10.1177/0300060520946872
14	Philipp Heumann, Andreas Albert, Karsten Gülow, Deniz Tümen, Martina Müller, Arne Kandulski. Insights in Molecular Therapies for Hepatocellular Carcinoma. Cancers 2024; 16(10) doi: 10.3390/cancers16101831
15	Zejin Zhao, Haizhao Yi, Yue Xiao, Zhiyan Li, Jinlong Liu. Comparative effectiveness of several adjuvant therapies for patients with hepatocellular carcinoma with high-risk factors for recurrence after hepatectomy: a systematic review and meta-analysis. Frontiers in Medicine 2025; 12 doi: 10.3389/fmed.2025.1692417
16	Lin Zheng, Chen-Yang Guo, Cheng-Shi Chen, Jin-Cheng Xiao, Hong-Tao Hu, Hong-Tao Cheng, Deng-Wei Zong, Li Jiang, Hai-Liang Li. Sorafenib improves lipiodol deposition in transarterial chemoembolization of Chinese patients with hepatocellular carcinoma: a long-term, retrospective study. Oncotarget 2017; 8(57) doi: 10.18632/oncotarget.18811
17	Noura Gamal, Rasha Abdelhafiz Aly, Alzhraa Alkhatib, Asmaa Gomaa, Naglaa Allam, Imam Waked. Adjuvant anti-PD-L1 therapy for hepatocellular carcinoma following curative treatment: case series. Egyptian Liver Journal 2026; 16(1) doi: 10.1186/s43066-025-00460-w
18	Valentina Zanuso, Lorenza Rimassa, Chiara Braconi. The rapidly evolving landscape of HCC: Selecting the optimal systemic therapy. Hepatology 2025; 81(4) doi: 10.1097/HEP.0000000000000572
19	Masataka Amisaki, Hiroaki Saito, Naruo Tokuyasu, Teruhisa Sakamoto, Soichiro Honjo, Yoshiyuki Fujiwara. Prognostic value of postoperative complication for early recurrence after curative resection of hepatocellular carcinoma. Hepatobiliary & Pancreatic Diseases International 2018; 17(4) doi: 10.1016/j.hbpd.2018.03.016
20	雪瑞房. Retrospective Efficacy and Safety Analysis of Prophylactic Transarterial Chemoembolization (TACE) and Targeted Immunotherapy after Primary Liver Cancer Resection. Journal of Clinical Personalized Medicine 2025; 4(03) doi: 10.12677/jcpm.2025.43382
21	Lei Wang, Chunhong Xiao, Ren Wang, Jingbo Chen, Weiping Zhou, Jingfeng Liu, Nanping Lin, Kongying Lin. The Clinical Value of Postoperative Transarterial Chemoembolization for Resectable Patients with Intermediate Hepatocellular Carcinoma After Radical Hepatectomy: a Propensity Score-Matching Study. Journal of Gastrointestinal Surgery 2021; 25(5) doi: 10.1007/s11605-020-04588-5
22	Sha She, Jinzhi Shi, Jiling Zhu, Fan Yang, Jia Yu, Kai Dai. Impact of inflammation and the immune system on hepatocellular carcinoma recurrence after hepatectomy. Cancer Medicine 2024; 13(4) doi: 10.1002/cam4.7018
23	Han Ah Lee, Yeon Seok Seo, In-Soo Shin, Won Sup Yoon, Hye Yoon Lee, Chai Hong Rim. Efficacy and feasibility of surgery and external radiotherapy for hepatocellular carcinoma with portal invasion: A meta-analysis. International Journal of Surgery 2022; 104 doi: 10.1016/j.ijsu.2022.106753
24	Qingli Li, Tianqiang Song. Association Between Adjuvant Sorafenib and the Prognosis of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.633033
25	Hiroto Matsui Matsui, Shoichi Hazama, Masao Nakajima, Ming Xu, Satoshi Matsukuma, Yukio Tokumitsu, Yoshitaro Shindo, Shinobu Tomochika, Shin Yoshida, Michihisa Iida, Nobuaki Suzuki, Shigeru Takeda, Shigefumi Yoshino, Tomio Ueno, Masaaki Oka, Hiroaki Nagano. Novel adjuvant dendritic cell therapy with transfection of heat-shock protein 70 messenger RNA for patients with hepatocellular carcinoma: a phase I/II prospective randomized controlled clinical trial. Cancer Immunology, Immunotherapy 2021; 70(4) doi: 10.1007/s00262-020-02737-y
26	Jianming Yang, Shijie Jiang, Yewu Chen, Jian Zhang, Yinan Deng. Adjuvant ICIs Plus Targeted Therapies Reduce HCC Recurrence after Hepatectomy in Patients with High Risk of Recurrence. Current Oncology 2023; 30(2) doi: 10.3390/curroncol30020132
27	G.K. Glantzounis, A. Paliouras, M.-C. Stylianidi, H. Milionis, P. Tzimas, D. Roukos, G. Pentheroudakis, E. Felekouras. The role of liver resection in the management of intermediate and advanced stage hepatocellular carcinoma. A systematic review. European Journal of Surgical Oncology 2018; 44(2) doi: 10.1016/j.ejso.2017.11.022
28	Zun-Yi Zhang, Er-Lei Zhang, Bi-Xiang Zhang, Xiao-Ping Chen, Wei Zhang. Treatment for hepatocellular carcinoma with tumor thrombosis in the hepatic vein or inferior vena cava: A comprehensive review. World Journal of Gastrointestinal Surgery 2021; 13(8): 796-805 doi: 10.4240/wjgs.v13.i8.796 Abstract(1032) \| Core Tip(1092) \| Full Article(HTML)(7876) \| Full Article (PDF)-3408K(624) \| Full Article (Word)-716K(245) \| Audio-474K(21) \| Peer-Review Report-564K(275) \| Answering Reviewers-45K(244) \| Times Cited (9) \| Total Visits (10161) \| Open
29	Yifei Tan, Qing Xu, Zhenru Wu, Wei Zhang, Bo Li, Bohan Zhang, Xi Xu, Bo Zhang, Ke Yan, Jiulin Song, Tao Lv, Jian Yang, Li Jiang, Yujun Shi, Jiayin Yang, Lunan Yan. Overexpression of PD-L1 is an Independent Predictor for Recurrence in HCC Patients Who Receive Sorafenib Treatment After Surgical Resection. Frontiers in Oncology 2022; 11 doi: 10.3389/fonc.2021.783335
30	Wei Zhang, Bixiang Zhang, Xiao-ping Chen. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma. Frontiers of Medicine 2021; 15(2) doi: 10.1007/s11684-021-0848-3
31	Zhi-Ming Zeng, Ning Mo, Jie Zeng, Fu-Chao Ma, Yan-Feng Jiang, Hua-Sheng Huang, Xi-Wen Liao, Guang-Zhi Zhu, Jie Ma, Tao Peng. Advances in postoperative adjuvant therapy for primary liver cancer. World Journal of Gastrointestinal Oncology 2022; 14(9): 1604-1621 doi: 10.4251/wjgo.v14.i9.1604 Abstract(1052) \| Core Tip(1157) \| Full Article(HTML)(5915) \| Full Article (PDF)-772K(512) \| Full Article (Word)-175K(114) \| Audio-1282K(12) \| Peer-Review Report-362K(242) \| Answering Reviewers-292K(265) \| Times Cited (30) \| Total Visits (7090) \| Open
32	Jeng-Shiun Du, Shih-Hsien Hsu, Shen-Nien Wang. The Current and Prospective Adjuvant Therapies for Hepatocellular Carcinoma. Cancers 2024; 16(7) doi: 10.3390/cancers16071422
33	Jin Shang, Shanling Xu, Jiaxing Zhang, Xuting Ran, Lang Bai, Hong Tang. Efficacy of sorafenib in patients with hepatocellular carcinoma after resection: a meta-analysis. Oncotarget 2017; 8(65) doi: 10.18632/oncotarget.21299
34	Bin Guo, Qian Chen, Zhicheng Liu, Xiaoping Chen, Peng Zhu. Adjuvant therapy following curative treatments for hepatocellular carcinoma: current dilemmas and prospects. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1098958
35	Shenglan Huang, Dan Li, LingLing Zhuang, Liying Sun, Jianbing Wu. A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection. World Journal of Surgical Oncology 2021; 19(1) doi: 10.1186/s12957-021-02280-9
36	Shashank Kumar, Abhay Kumar Pandey. Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma. Current Oncology 2023; 30(2) doi: 10.3390/curroncol30020105
37	Jiang Li, Fan Yang, Jian Li, Zhi-Yong Huang, Qi Cheng, Er-Lei Zhang. Postoperative adjuvant therapy for hepatocellular carcinoma with microvascular invasion. World Journal of Gastrointestinal Surgery 2023; 15(1): 19-31 doi: 10.4240/wjgs.v15.i1.19 Abstract(1064) \| Core Tip(1088) \| Full Article(HTML)(4454) \| Full Article (PDF)-635K(451) \| Full Article (Word)-145K(65) \| Audio-2084K(30) \| Peer-Review Report-220K(165) \| Answering Reviewers-120K(190) \| Times Cited (12) \| Total Visits (5892) \| Open
38	Sarwat Fatima, Nikki Pui-Yue Lee, Hiu Yee Kwan, Zhao Xiang Bian. Hepatocellular Carcinoma - Advances in Diagnosis and Treatment. 2018; doi: 10.5772/intechopen.71480
39	Zun-Yi Zhang, Er-Lei Zhang, Bi-Xiang Zhang, Wei Zhang. Surgery for hepatocellular carcinoma with tumor thrombosis in inferior vena cava: A case report. World Journal of Clinical Cases 2021; 9(36): 11495-11503 doi: 10.12998/wjcc.v9.i36.11495 Abstract(981) \| Core Tip(830) \| Full Article(HTML)(2865) \| Full Article (PDF)-19764K(457) \| Full Article (Word)-771K(166) \| Audio-795K(12) \| Peer-Review Report-219K(263) \| Answering Reviewers-37K(299) \| Times Cited (1) \| Total Visits (4248) \| Open
40	Chen Jue, Wu Zhifeng, Zhang Zhisheng, Cui Lin, Qian Yayun, Jin Feng, Gu Hao, Ishikawa Shintaro, Tadashi Hisamitsu, Guo Shiyu, Liu Yanqing. Vasculogenic mimicry in hepatocellular carcinoma contributes to portal vein invasion. Oncotarget 2016; 7(47) doi: 10.18632/oncotarget.12867
41	Chang-Zhi Chen, Jian-Hong Zhong, Ya-Peng Qi, Jie Zhang, Tao Huang, Liang Ma, Le-Qun Li, Tao Peng, Bang-De Xiang. Development of a preoperative prognostic scoring system to predict benefits of hepatic resection in advanced hepatocellular carcinoma patients. Bioscience Reports 2021; 41(4) doi: 10.1042/BSR20201928
42	Zi-Wen Tao, Bao-Quan Cheng, Tao Zhou, Yan-Jing Gao. Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review. Hepatobiliary & Pancreatic Diseases International 2022; 21(2) doi: 10.1016/j.hbpd.2021.12.004